🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join me and my colleagues to celebrate the 40th anniversary of CFS®. We will be discussing the latest topics in oncology and practice-changing strategies for diagnosis, treatment, and supportive care. Register now for free with code: CFS22NAFREE bit.ly/3OdCITO

Though less common, the disease is often far along once it's discovered. This is what you need to know. huffpost.com/entry/male-bre… via HuffPost Life

#SABCS22 is 4 weeks away! Excited for #bcsm updates including overall survival data, novel compound activity, tx sequencing info, molecular data to inform tx decision, & info about pregnancy post cancer. Attached are the top 10 (yes, I cheated) I'm excited to see! @oncoalert

There is nothing better on the internet today than Sofiane Boufal celebrating today's win with his mother. 🇲🇦❤️

Sacituzumab Govitecan, Trastuzumab Deruxtecan Highlight Expanding Role of ADCs in TNBC Nour Abuhadra Memorial Sloan Kettering Cancer Center PER #gotoCFS #CFS22 #CFS2022 #bcsm ow.ly/ReT250M6bYy

#tnbc #MpBC #Bcsm Just opened phase 1/2 study for orphan and lethal metastatic Metaplastic breast cancer. Supported by NCI U01, pts receive drugs that block the two oncogenic drivers of this rare disease - PI3K & iNOS (LNMMA). Preclinical data stunning. All referrals please

Honored to receive a 2023 ASCO Career Development Award that will support our efforts to characterize the TME in metaplastic breast cancer and identify predictors of response to immunotherapy! Grateful to my mentors @MarkRobsonMD & Sarat Chandarlapaty Memorial Sloan Kettering Cancer Center Metaplastic Breast Cancer Global Alliance

It takes a special kind of village to advocate for a rare breast cancer… thank you Metaplastic Breast Cancer Global Alliance for all that you do for our #MetaplasticBreastCancer patients and for your support! 🙏🏼

A single-cell analysis of tumor-infiltrating T cells from 16 cancer types identifies new T cell subsets and a stress response cell state enriched in tumors resistant to immunotherapy. nature.com/articles/s4159…

Time for part ✌️of our early stage ER+ #breastcancer discussion! Let's round our great discussion, focusing on more high yield topics you need to know to care for your patients (& for exams!) #ICYMI highly recommend checking out episode 057 first! Link in bio! #BCSM #ASCO23

We heard from coordinators that this trial is opening enrollment soon. Most #Metaplasticbreastcancer cases are #triplenegativebreastcancer, so we wanted to spread the word 📣 clinicaltrials.gov/ct2/show/NCT05…

Excited to share our work demonstrating that integrating Ki-67 and sTIL enhances prediction of pCR in TNBC (pCR 65% with neoadjuvant chemo alone). This model may refine the selection of early-stage TNBC patients for neoadjuvant clinical trials evaluating de-escalation strategies.

Featured today by MSK Library: Molecularly Targeted Therapies for #TripleNegative #BreastCancer: History, Advances, and Future Directions: dx.doi.org/10.1016/j.clbc… Nour Abuhadra Komal Jhaveri

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial | Cardiology | JAMA | JAMA Network jamanetwork.com/journals/jama/…

Many molecular targets are identified & validated in the treatment of TNBC including the (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway as seen below. Read more about targeted therapies in TNBC 👇 Nour Abuhadra Komal Jhaveri Nicholas Mai #bcsm sciencedirect.com/science/articl…

MSK's Rare Breast Cancer Program, led by Nour Abuhadra + Giacomo Montagna, MD, MPH, treats people with rare breast tumors and advances research. Learn more about how Michelle, an MSK patient w/ metaplastic #breastcancer, was treated by Pedram Razavi + team. mskcc.org/news/msks-rare…

🧬 TWEETORIAL/X'torial: Why Every Rare Cancer Patient Deserves Molecular Profiling 🧬 1/15 🚨 Here's a shocking fact: Rare cancers make up 25% of ALL cancer cases, yet most patients never get the molecular testing that could save their lives. 👉In our policy & practice paper -